Peregrine Pharmaceuticals, Inc. (Peregrine) is a clinical-stage biopharmaceutical company that manufactures and develops monoclonal antibodies for the treatment of cancer and viral infections. The Company is advancing three separate clinical programs with its compounds bavituximab and Cotara that are clinical candidates under its anti-phosphatidylserine (Anti-PS) therapeutics and tumor necrosis therapy (TNT) platforms. In addition to its clinical programs, Peregrine is performing pre-clinical research on bavituximab and an equivalent human antibody as a potential treatment for viral hemorrhagic fever infections under a contract awarded through the Transformational Medical Technologies Initiative (TMTI) of the United States Department of Defense's Defense Threat Reduction Agency (DTRA).